plenti cmv blast dest addgene plasmid (Addgene inc)
Addgene inc is a verified supplier 
94
Structured Review
Addgene inc
plenti cmv blast dest addgene plasmid
Plenti Cmv Blast Dest Addgene Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 106 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plenti+cmv+blast+dest/pLenti+CMV+Blast+DEST+(706-1)+(Plasmid+%2317451)/pm41843626-273-199-203
Average 94 stars, based on 106 article reviews
Plenti Cmv Blast Dest Addgene Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 106 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plenti+cmv+blast+dest/pLenti+CMV+Blast+DEST+(706-1)+(Plasmid+%2317451)/pm41843626-273-199-203
Average 94 stars, based on 106 article reviews
plenti cmv blast dest addgene plasmid - by Bioz Stars,
2026-09
94/100 stars
Images
Related Articles
Control:Article Title: Autocrine TGFβ2 enforces a transcriptionally hybrid cell state in Ewing sarcoma Article Snippet: For each well, 0.87 μg of transfer plasmid, 0.42 μg psPax2 (Addgene #12260), and 0.21 μg pMD2.G (Addgene #12259) were combined with 21 μL polyethyleneimine (PEI, 1 μg/μL) in FreeStyleTM 293 Expression Medium (ThermoFisher, Cat. #12338018) using a Hamilton Starlet liquid handler. .. The transfer plasmids utilized in this study included Article Title: p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2 + breast cancer that limits trastuzumab deruxtecan efficacy. Article Snippet: Resistance to human epidermal growth factor receptor 2 (HER2)-targeted therapies and immuno-oncology agents poses a major challenge in treating HER2-positive breast cancer.. Here we demonstrate that p95HER2, a truncated form of HER2, drives immune evasion in HER2-positive female breast cancer, enhancing tumor growth and conferring therapy resistance.. This stems from the unique ability of p95HER2 to promote cancer cell-intrinsic programmed death ligand 1 expression and secretion of immunosuppressive mediators including interleukin 6. Article Title: Autocrine TGFβ2 enforces a transcriptionally hybrid cell state in Ewing sarcoma Article Snippet: For each well, 0.87 μg of transfer plasmid, 0.42 μg psPax2 (Addgene #12260), and 0.21 μg pMD2.G (Addgene #12259) were combined with 21 μl of polyethyleneimine (PEI; 1 μg/μl) in FreeStyle 293 Expression Medium (Thermo Fisher Scientific, catalog no. 12338018) using a Hamilton Starlet liquid handler. .. The transfer plasmids used in this study included Construct:Article Title: p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2 + breast cancer that limits trastuzumab deruxtecan efficacy. Article Snippet: Resistance to human epidermal growth factor receptor 2 (HER2)-targeted therapies and immuno-oncology agents poses a major challenge in treating HER2-positive breast cancer.. Here we demonstrate that p95HER2, a truncated form of HER2, drives immune evasion in HER2-positive female breast cancer, enhancing tumor growth and conferring therapy resistance.. This stems from the unique ability of p95HER2 to promote cancer cell-intrinsic programmed death ligand 1 expression and secretion of immunosuppressive mediators including interleukin 6. Expressing:Article Title: p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2 + breast cancer that limits trastuzumab deruxtecan efficacy. Article Snippet: Resistance to human epidermal growth factor receptor 2 (HER2)-targeted therapies and immuno-oncology agents poses a major challenge in treating HER2-positive breast cancer.. Here we demonstrate that p95HER2, a truncated form of HER2, drives immune evasion in HER2-positive female breast cancer, enhancing tumor growth and conferring therapy resistance.. This stems from the unique ability of p95HER2 to promote cancer cell-intrinsic programmed death ligand 1 expression and secretion of immunosuppressive mediators including interleukin 6. Article Title: Metabolomics analysis of SNAT2-deficient cells: Implications for the discovery of selective small-molecule inhibitors of an amino acid transporter Article Snippet: .. To clone the lentiviral expression vector for human SNAT1, we used Gateway LR Clonase II (Invitrogen; catalog no.: 11791020) to combine pDONR221-SLC38A1-STOP (Addgene; catalog no.: 161261) and Plasmid Preparation:Article Title: p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2 + breast cancer that limits trastuzumab deruxtecan efficacy. Article Snippet: Resistance to human epidermal growth factor receptor 2 (HER2)-targeted therapies and immuno-oncology agents poses a major challenge in treating HER2-positive breast cancer.. Here we demonstrate that p95HER2, a truncated form of HER2, drives immune evasion in HER2-positive female breast cancer, enhancing tumor growth and conferring therapy resistance.. This stems from the unique ability of p95HER2 to promote cancer cell-intrinsic programmed death ligand 1 expression and secretion of immunosuppressive mediators including interleukin 6. Article Title: DGAT1 as a Racially Divergent Driver of Carcinoma-Associated Fibroblast Activation Drives Tumorigenic Pathways via ERK1/2 Signaling in Prostate Cancer Article Snippet: DGAT1 expressing plasmid was obtained from GenScript (OHU 28798) and subcloned into pENTR1A-GFP-N2 (FR1) (gift from Eric Campeau & Paul Kaufman, plasmid # 19364, Addgene, Watertown, MA, USA) using the In-Fusion Snap Assembly Bundle (638945, Takara, Shiga, Japan). .. Entry clone, pENTR1A-DGAT1-GFP-N2 was cloned into Transformation Assay:Article Title: Metabolomics analysis of SNAT2-deficient cells: Implications for the discovery of selective small-molecule inhibitors of an amino acid transporter Article Snippet: .. To clone the lentiviral expression vector for human SNAT1, we used Gateway LR Clonase II (Invitrogen; catalog no.: 11791020) to combine pDONR221-SLC38A1-STOP (Addgene; catalog no.: 161261) and Clone Assay:Article Title: PROCA11 early activation fuels prostate cancer neuroendocrine traits by regulating cell survival and migration Article Snippet: The PROCA11 cDNA was obtained by reverse transcription and PCR with primers complementary to 5′ and 3′ extremities of the gene, V1, V2 and V3 amplicons were resolved in the 1% agarose gel and purified using the gel purification kit (Qiagen). .. Each cDNA was cloned into pDONR201 (Invitrogen) and further sub-cloned into Article Title: PROCA11 early activation fuels prostate cancer neuroendocrine traits by regulating cell survival and migration Article Snippet: The PROCA11 cDNA was obtained by reverse transcription and PCR with primers complementary to 5 ′ and 3 ′ extremities of the gene, V1, V2 and V3 amplicons were resolved in the 1% agarose gel and purified using the gel purification kit (Qiagen). .. Each cDNA was cloned into pDONR201 (Invitrogen) and further sub-cloned into Article Title: DGAT1 as a Racially Divergent Driver of Carcinoma-Associated Fibroblast Activation Drives Tumorigenic Pathways via ERK1/2 Signaling in Prostate Cancer Article Snippet: DGAT1 expressing plasmid was obtained from GenScript (OHU 28798) and subcloned into pENTR1A-GFP-N2 (FR1) (gift from Eric Campeau & Paul Kaufman, plasmid # 19364, Addgene, Watertown, MA, USA) using the In-Fusion Snap Assembly Bundle (638945, Takara, Shiga, Japan). .. Entry clone, pENTR1A-DGAT1-GFP-N2 was cloned into |